Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 12.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,982,354 shares of the company’s stock after selling 291,841 shares during the quarter. BNP Paribas Financial Markets’ holdings in Karyopharm Therapeutics were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics in the second quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $143,000. Acadian Asset Management LLC acquired a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $167,000. Exchange Traded Concepts LLC grew its position in Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares during the period. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Price Performance

KPTI opened at $0.77 on Friday. The business has a 50 day moving average price of $0.85 and a two-hundred day moving average price of $0.87. The company has a market capitalization of $96.27 million, a price-to-earnings ratio of -0.67 and a beta of 0.05. Karyopharm Therapeutics Inc. has a 1-year low of $0.62 and a 1-year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same quarter last year, the company earned ($0.30) EPS. Equities analysts expect that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KPTI. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Finally, Piper Sandler lifted their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).